Villela LM, Bolaños-Meade J

Idioma: Español
Referencias bibliográficas: 20
Paginas: 86-89
Archivo PDF: 70.72 Kb.

RESUMEN

La prevención efectiva de la enfermedad de injerto contra huésped es uno de los retos más importantes para el médico especializado en trasplante de células troncales hematopoyéticas. Aunque existen esquemas que producen resultados similares (y presuntamente “adecuados”), generalmente estos se asocian con el uso prolongado de inmunosupresión y relativamente elevadas tasas de enfermedad de injerto contra huésped crónica. La ciclofosfamida en altas dosis (50 mg/kg/día los días +3 y +4) se asocia con tasas bajas de enfermedad de injerto contra huésped aguda (particularmente de grados III y IV) y crónica (cercanas al 10% únicamente) y permiten el trasplante entre parejas que son discordantes en el perfil HLA (haploidénticos). En este artículo se revisan los estudios clínicos que han utilizado esta estrategia y se resaltan las ventajas potenciales para los pacientes en México.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bolaños-Meade J, Vogelsang GB. Acute graft-versus-host disease. Clinical Advances in Hematology & Oncology 2004;2(10):672-682.

2. Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005;106(9):3308-3313.

3. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98(10):2942-2947.

4. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373(9674):1550-1561.

5. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128(2):255-266.

6. Sladek NE, Kollander R, Sreerama L, Kiang DT. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamidebased chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 2002; 49(4):309-321.

7. Jones RJ, Barber JP, Vala MS et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995; 85(10):2742-2746.

8. Brodsky RA, Sensenbrenner LL, Smith BD et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001; 135(7):477-483.

9. Owens AH, Santos GW. The effect of cytotoxic drugs on graftversus-host disease in mice. Transplantation 1971;11(4):378-382.

10. Glucksberg H, Fefer A. Chemotherapy of established graftversus- host disease in mice. Transplantation 1972; 13(3):300-305.

11. Santos GW, Tutschka PJ, Brookmeyer R. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized, double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987;1:21-28.

12. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and postransplantation cyclophosphamide. Blood 2001; 98(12):3456-3464.

13. O’Donnell PV, Luznik L, Jones RJ et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using postransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8(7):377-386.

14. Luznik L, O’Donnell PV, Symons HJ et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14(6):641-650.

15. Fuchs EJ, Luznik L, Bolaños-Meade J et al. Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant 2009; 43(12):969-970.

16. Fuchs EJ, Wu J, Carter S et al. Phase II Trial of Non- Myeloablative Conditioning and Partially HLA-Mismatched (HLA-Haploidentical) Bone Marrow Transplantation (BMT) for Patients With Hematologic Malignancies: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0603. Biology of Blood and Marrow Transplantation 2011; 17(2, Supplement 1):S151.

17. Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010;16(4):482-489.

18. Bolaños-Meade J, Lanzkron S, Kemberling H et al. Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation (haplo-BMT) With Post-Transplant High-Dose Cyclophosphamide (Cy) in Patients With Severe Hemoglobinopathies. Biology of Blood and Marrow Transplantation 2011;17(2, Supplement 1):S285.

19. Brodsky RA, Luznik L, Bolaños-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant 2008; 42(8):523-527.

20. Luznik L, Bolaños-Meade J, Zahurak M et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115(16):3224-3230.